Gender differences in subjective stress and neuroendocrine response to a stress task among individuals with opioid dependence: A pilot study.
Cortisol
Dephydroepiandrostrone
Gender differences
Heart rate
Opioid dependence
Stress
Journal
Addictive behaviors
ISSN: 1873-6327
Titre abrégé: Addict Behav
Pays: England
ID NLM: 7603486
Informations de publication
Date de publication:
05 2019
05 2019
Historique:
received:
24
09
2018
revised:
17
12
2018
accepted:
17
12
2018
pubmed:
15
1
2019
medline:
14
7
2020
entrez:
15
1
2019
Statut:
ppublish
Résumé
Opioid dependence is a significant public health problem in the United States and the number of opioid overdose deaths among women has increased dramatically in comparison to men in the last few years. In this context, understanding the biological mechanisms underlying gender differences in vulnerability to opioid dependence is essential. The current pilot study examined gender differences in subjective stress, heart rate (HR), and cortisol/dephydroepiandrosterone (DHEA) response to a laboratory stressor (Trier Social Stress Test; TSST) or a no-stress condition, and drug cue paradigm among men (n = 21) and women (n = 18) with opioid dependence. Significant group (TSST vs. no stress) differences emerged in self-reported stress [F(1,35) = 23.8, p < .001], HR [F(1,31) = 12.3; p = .001] and cortisol (F Although women with opioid dependence reported greater subjective stress when exposed to a laboratory stress paradigm as compared to men, the neuroendocrine response was more robust in men. This pattern was similar to gender findings in men and women with cocaine and tobacco use disorders. The blunted cortisol combined with an increased subjective response among women may be a sign of HPA axis dysregulation which could increase vulnerability to relapse in women.
Sections du résumé
BACKGROUND
Opioid dependence is a significant public health problem in the United States and the number of opioid overdose deaths among women has increased dramatically in comparison to men in the last few years. In this context, understanding the biological mechanisms underlying gender differences in vulnerability to opioid dependence is essential.
METHODS
The current pilot study examined gender differences in subjective stress, heart rate (HR), and cortisol/dephydroepiandrosterone (DHEA) response to a laboratory stressor (Trier Social Stress Test; TSST) or a no-stress condition, and drug cue paradigm among men (n = 21) and women (n = 18) with opioid dependence.
RESULTS
Significant group (TSST vs. no stress) differences emerged in self-reported stress [F(1,35) = 23.8, p < .001], HR [F(1,31) = 12.3; p = .001] and cortisol (F
CONCLUSIONS
Although women with opioid dependence reported greater subjective stress when exposed to a laboratory stress paradigm as compared to men, the neuroendocrine response was more robust in men. This pattern was similar to gender findings in men and women with cocaine and tobacco use disorders. The blunted cortisol combined with an increased subjective response among women may be a sign of HPA axis dysregulation which could increase vulnerability to relapse in women.
Identifiants
pubmed: 30640146
pii: S0306-4603(18)31095-5
doi: 10.1016/j.addbeh.2018.12.022
pmc: PMC6499664
mid: NIHMS1518466
pii:
doi:
Substances chimiques
Hydrocortisone
WI4X0X7BPJ
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
148-154Subventions
Organisme : NIDA NIH HHS
ID : U54 DA016511
Pays : United States
Organisme : NIAAA NIH HHS
ID : L30 AA025230
Pays : United States
Organisme : NIDA NIH HHS
ID : K23 DA036566
Pays : United States
Organisme : NIDA NIH HHS
ID : K23 DA042935
Pays : United States
Organisme : NIDA NIH HHS
ID : K23 DA021228
Pays : United States
Organisme : NIDA NIH HHS
ID : K23 DA039318
Pays : United States
Organisme : NIMH NIH HHS
ID : T32 MH018869
Pays : United States
Informations de copyright
Copyright © 2019 Elsevier Ltd. All rights reserved.
Références
Neuropsychopharmacology. 2004 Aug;29(8):1546-57
pubmed: 15199367
Am J Psychiatry. 1993 Nov;150(11):1707-11
pubmed: 8214180
Control Clin Trials. 1988 Dec;9(4):345-64
pubmed: 3203525
Psychiatr Clin North Am. 2010 Jun;33(2):339-55
pubmed: 20385341
J Neurosci Res. 2017 Jan 2;95(1-2):320-327
pubmed: 27870396
Brain Res. 2016 Jun 15;1641(Pt B):177-88
pubmed: 26607253
Psychoneuroendocrinology. 2017 Aug;82:26-37
pubmed: 28486178
J Abnorm Psychol. 1997 May;106(2):243-50
pubmed: 9131844
Ann Intern Med. 2017 Sep 5;167(5):293-301
pubmed: 28761945
Am J Drug Alcohol Abuse. 2011 Sep;37(5):313-23
pubmed: 21854273
J Subst Abuse Treat. 2018 Apr;87:79-85
pubmed: 29433788
Neuropsychopharmacology. 2014 May;39(6):1527-37
pubmed: 24395021
J Neurosci. 2001 Jul 1;21(13):RC152
pubmed: 11406637
J Subst Abuse. 1998;10(1):27-42
pubmed: 9720004
MMWR Morb Mortal Wkly Rep. 2013 Jul 5;62(26):537-42
pubmed: 23820967
MMWR Morb Mortal Wkly Rep. 2015 Jul 10;64(26):719-25
pubmed: 26158353
Addict Behav. 2017 Feb;65:229-235
pubmed: 27561431
J Subst Abuse Treat. 1986;3(3):173-9
pubmed: 3806730
Nicotine Tob Res. 2015 Apr;17(4):486-95
pubmed: 25762760
Psychoneuroendocrinology. 2017 Sep;83:135-141
pubmed: 28623762
Psychoneuroendocrinology. 2008 Jun;33(5):560-8
pubmed: 18321653
Arch Gen Psychiatry. 2009 Apr;66(4):422-30
pubmed: 19349312
Neuroscience. 2001;106(2):375-84
pubmed: 11566507
Alcohol Alcohol. 2003 Mar-Apr;38(2):189-93
pubmed: 12634269
Alcohol Clin Exp Res. 2006 Jun;30(6):938-46
pubmed: 16737451
Psychopharmacology (Berl). 2011 Mar;214(1):367-75
pubmed: 20838776
Am J Psychiatry. 2004 Feb;161(2):195-216
pubmed: 14754765
J Neurosci. 2004 May 12;24(19):4576-84
pubmed: 15140929
Addict Behav. 2010 Nov;35(11):1001-7
pubmed: 20598809
Drug Alcohol Depend. 2015 Oct 1;155:60-7
pubmed: 26342626
Psychopharmacology (Berl). 2014 Oct;231(21):4157-65
pubmed: 24710621
Psychopharmacology (Berl). 2001 Dec;158(4):343-59
pubmed: 11797055
Neuropsychopharmacology. 2006 Mar;31(3):544-54
pubmed: 16123744
Psychiatr Clin North Am. 1999 Jun;22(2):241-52
pubmed: 10385931
Neuropsychopharmacology. 2003 May;28(5):985-94
pubmed: 12700714
Biol Psychiatry. 2001 Jun 15;49(12):1023-39
pubmed: 11430844
Psychiatry (Edgmont). 2007 May;4(5):35-40
pubmed: 20806028
Psychopharmacology (Berl). 2008 Jan;195(4):527-36
pubmed: 17891383
Psychopharmacology (Berl). 2005 Aug;181(1):107-17
pubmed: 15834539
Neuropsychobiology. 1993;28(1-2):76-81
pubmed: 8255414
J Psychopharmacol. 2015 Mar;29(3):300-11
pubmed: 25516371